HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative immunotherapies aimed at extending healthspan by addressing the connection between inflammation and age-related diseases. The Company has recently shared its financial results and key business highlights for the second quarter.
Key Milestones Achieved
Dr. Hing C. Wong, the Founder and CEO of HCW Biologics, announced a significant achievement for the company. They have successfully reached a settlement agreement concerning an arbitration that had posed a major hurdle to their growth for nearly two years. Following this resolution, HCW Biologics has swiftly initiated a comprehensive financing strategy, which includes a prominent equity offering and an enhanced out-licensing initiative. The Company is optimistic about its future, particularly with the TOBI™ platform and a strong portfolio of TOBI™-based molecules. Their focus is on developing next-generation immunotherapeutics, informed by human data from early clinical trial phases. A key area of concentration remains the treatment of senescence-associated disorders, especially those common in age-related diseases like cancer.
Recent Developments
Several noteworthy business highlights have emerged, including:
On a recent date, the Company entered into a confidential Settlement Agreement to resolve the arbitration initiated against it and Dr. Hing C. Wong, which involved mutual releases among the parties. Importantly, no monetary damages were exchanged as part of this settlement.
HCW Biologics retains complete ownership and control over the TOBI™ platform and its related molecules, with no restrictions on their use for non-oncology purposes. Additionally, the Company is set to advance clinical developments for HCW9302, HCW9206, and HCW9201 related to cancer indications.
A refreshed financing strategy has been launched, including an equity offering expected to close before the year ends, along with ongoing discussions with potential licensing partners for out-licensing non-core assets.
Financial Summary for Second Quarter 2024
For the quarter ending June 30, 2024, the Company reported the following financial results:
- Revenues: The quarter's revenues totaled $618,854, showing a slight decrease from $622,807 during the same period last year. Over the first six months, total revenues reached approximately $1.7 million, compared to $664,690 in the previous year.
- Research and Development Expenses: R&D expenses rose to $2.0 million in Q2 2024, up from $1.6 million in the same quarter of 2023. For the first half of 2024, R&D expenses totaled $4.2 million, an increase from $3.9 million in the previous year.
- General and Administrative Expenses: G&A expenses remained steady at $1.6 million during Q2 2024, similar to the previous year, due to cost-cutting measures.
- Legal Expenses: Legal expenses surged to $10.4 million in Q2 2024, a significant increase from $1.4 million in the same quarter last year, primarily related to the Altor/NantCell matter.
- Net Loss: The Company recorded a net loss of $15.3 million for Q2 2024, compared to $4.3 million in the same quarter of 2023.
Financial Outlook
In 2024, HCW Biologics has secured $8.0 million in funding, which includes a private placement of common stock and the issuance of Secured Notes. The Company is authorized to raise an additional $10 million in Secured Notes, aiming for full subscriptions.
As of June 30, 2024, there are significant concerns regarding the Company’s ability to continue as a going concern without further financing or support.
Company Overview
HCW Biologics is dedicated to discovering and developing cutting-edge immunotherapies designed to extend healthspan by targeting chronic, low-grade inflammation associated with various age-related diseases, including cancer, cardiovascular diseases, and autoimmune disorders. The Company’s proprietary TOBI™ platform plays a central role in their research and product development strategy.
HCW Biologics is excited about the future of its clinical trials and product pipeline, with plans to initiate the clinical evaluation of HCW9302, which aims to treat autoimmune diseases by expanding regulatory T cells.
Company Contact
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
Frequently Asked Questions
What is HCW Biologics focused on?
HCW Biologics is committed to discovering and developing innovative immunotherapies that target inflammation and age-related diseases.
What recent financial results were announced?
For Q2 2024, HCW Biologics reported revenues of $618,854 and a net loss of $15.3 million.
What significant milestones has HCW Biologics achieved recently?
The Company successfully settled a long-standing arbitration and has launched a new equity offering and out-licensing program.
What are the projections for HCW Biologics' financing?
The Company plans to raise up to $10 million in Secured Notes and is exploring additional financing options moving forward.
Who can be contacted for more information regarding HCW Biologics?
For inquiries, please contact Rebecca Byam, CFO at HCW Biologics Inc.
